



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office. T-210 J, Shahpur Jat, New Delhi - 110 049 (INDIA)
Fax : 0091-11-26498341, 26494708, Phone : 0091-11-46181100, 46109900
CIN No. L74899DL1978PLC009181

Date: November 14th, 2019

To, The Department of Corporate Services- Listing Bombay Stock Exchange Ltd, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001	To, The Manager- Listing National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051
Scrp Code: 507789	Symbol: JAGSNPHARM

SUBJECT:- OUTCOME OF THE MEETING OF BOARD OF DIRECTORS OF JAGSONPAL PHARMACEUTICALS LIMITED HELD ON NOVEMBER 14TH, 2019

Dear Sir,

We wish to inform you that the Board of Directors of the Company at their meeting held today, (i.e. Thursday, the 14th Day of November, 2019), have inter alia, approved and taken on record the followings:

1. Un-Audited Financial Results of the Company for the Quarter and Half Year ended 30th September, 2019;
2. Limited Review Report for the Quarter and Half Year ended 30th September, 2019;
3. Appointment of Mr. Ashok Kumar Pati and Mr. Mammen Mathew as the Additional Non-Executive Independent Director on the Board w.e.f. 14th Day of November, 2019.
4. Took note of Appointment of Ms. Nandita Singh as the Company Secretary and Compliance Officer of the Company.

Further, the meeting was commenced at 12:00 Noon and concluded at 5:30 P.M.

Kindly take the above on record & oblige.

For JAGSONPAL PHARMACEUTICALS LIMITED



Nandita Singh
Company Secretary & Compliance Officer

**LIMITED REVIEW REPORT**

The Board of Directors
Jagsonpal Pharmaceuticals Limited
T-210-J, Shahpur Jat
New Delhi-110049

1. We have reviewed the accompanying statement of unaudited financial results of Jagsonpal Pharmaceuticals Limited (the "Company") for the quarter and six months ended 30th September, 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 14th November, 2019
Place: New Delhi

For H. L. Bansal & Co.
Firm Registration Number: 08563N
Chartered Accountants

H. L. Bansal
Proprietor

Membership Number: 086990

UDIN: 190869990AAA6L
2408




JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office: T-210 J, Shahpur Jat, New Delhi - 110 049 (INDIA)
 Fax : 0091-11-26498341, 26494708, Phone : 0091-11-46181100, 46109900
 CIN No. L74899DL1978PLC009181

Statement of Standalone Unaudited Financial Results for the Quarter and Half Year Ended 30.9.2019 Rs. in lacs

Particulars	Standalone					12 Months Year Ended 31.03.2019 Audited
	Quarter Ended			Half Year Ended		
	30.09.2019 Unaudited	30.06.2019 Unaudited	30.09.2018 Unaudited	30.09.2019 Unaudited	30.09.2018 Unaudited	
1 Income from operations						
a Gross Sales/Revenue from	4180.59	4523.40	4412.49	8703.99	8652.89	16682.56
b Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Total Income from operations	4180.59	4523.40	4412.49	8703.99	8652.89	16682.56
2 Other Income	44.38	67.12	18.30	111.50	27.09	142.90
3 Total Income [1+2]	4224.97	4590.52	4430.79	8815.49	8679.98	16825.46
4 Expenses						
a Cost of materials consumed	756.22	1173.13	990.99	1929.35	1841.55	3878.66
b Purchases of stock-in-trade	461.38	474.83	208.53	936.21	524.89	1464.08
c. Changes in inventories of finished goods, work in progress and Stock in trade	371.10	201.11	766.19	572.21	1734.56	1941.82
d. Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
e. Employee benefits expenses	1246.90	1314.51	1264.76	2561.41	2327.18	4661.1
f. Finance Cost	14.81	11.77	19.74	26.58	36.82	74.55
g. Depreciation and amortisation	26.72	28.61	24.99	55.33	50.39	101.58
h. Other expenses	1094.21	1136.10	934.35	2230.31	1852.44	3803.39
Total expenses	3971.34	4340.06	4209.55	8311.40	8367.83	15925.18
5 Profit before exceptional items and taxes (3-4)	253.63	250.46	221.24	504.09	312.15	900.28
6 Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
7 Profit before tax [5-6]	253.63	250.46	221.24	504.09	312.15	900.28
8 Tax expense	50.72	50.09	44.25	100.81	62.43	178.67
9 Net Profit for the period [7-8]	202.91	200.37	176.99	403.28	249.72	721.61
10 Other Comprehensive Income						
A (i) Items that will not be classified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
11 Total Other Comprehensive Income [A(i) + A(ii)]	0.00	0.00	0.00	0.00	0.00	0.00
12 Total Comprehensive Income [9+11]	202.91	200.37	176.99	403.28	249.72	721.61
13 Paid up Equity Share Capital (Face value Rs. 5/- per share)	1309.90	1309.90	1309.90	1309.90	1309.90	1309.90
14 Earnings Per Share (before and after extraordinary items)						
a. Basic (Rs.)	0.77	0.76	0.68	1.54	0.95	2.75
b. Diluted (Rs.)	0.77	0.76	0.68	1.54	0.95	2.75



Statement of Assets and Liabilities		
Particulars	As on 30.09.2019 (Unaudited)	As on 31.03.2019 (Audited)
ASSETS		
1 Non-current assets		
(a) Property , Plant and Equipment	2198.58	2161.39
(b) Capital Work-in-Progress	224.99	189.15
(c) Goodwill	3.00	3.00
development	206.27	206.27
(e) Financial assets		
(i) Investments	134.25	0.05
(f) Other non-current assets	1265.09	1262.72
Total non-current assets	4032.18	3822.58
2 Current assets		
(a) Inventories	2548.37	3269.26
(b) Financial assets		
(i) Trade receivables	2872.95	2075.02
(ii) Cash and Cash equivalents	51.57	35.70
above	4425.31	3817.76
(c) Other current assets	581.19	558.09
Total current assets	10479.39	9755.83
TOTAL ASSETS	14511.57	13578.41
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity Share Capital	1309.90	1309.90
(b) Other Equity		
(i) Reserves & Surplus	9540.69	9137.41
Total Equity	10850.59	10447.31
LIABILITIES		
1 Non-current liabilities		
(a) Deferred tax liabilities (Net)	311.91	311.91
(b) Non current borrowings	0.00	0.00
Non-current liabilities	311.91	311.91
2 Current Liabilities		
(a) Financial Liabilities		
(i) Trade payables	1410.37	1186.04
(II) Short term borrowings	448.98	378.54
(b) Other current liabilities	694.26	559.97
(c) Provision for tax	795.46	694.64
Total current liabilities	3349.07	2819.19
Total Liabilities	3660.98	3131.10
TOTAL - EQUITY AND LIABILITIES	14511.57	13578.41



Statement of Unaudited Cash flows for the Half Year Ended 30th September 2019

	Particulars	Standalone	
		Unaudited	Audited
		Six Months ended Sep 30,2019	Year ended March 31,2019
A.	<u>Cash flow from operating activities</u>		
	Profit before taxation	504.09	900.28
	Adjustments to reconcile profit & loss to net cash provided by operating activities:		
	Depreciation and amortisation	55.33	101.58
	Finance costs	26.58	74.55
	Other Income	-111.50	-142.90
	Operating profit before working capital changes	474.50	933.51
	Adjustments for:		
	(Increase/Decrease in Trade and Other Receivables	797.93	-440.34
	(Increase/Decrease in Financial Assets & Other Non Current Assets	2.37	178.49
	(Increase)/Decrease in Inventories	-720.89	-1874.12
	(Increase)/Decrease in Current assets	23.10	206.77
	(Increase)/Decrease in Trade and Others Payables	-459.44	-412.40
	Net Cash generated from / (used) in Operating Activities	356.93	2341.60
	Taxes (Paid)/ Refund (net)	-100.81	-185.28
	Net Cash generated from / (used) in Operating Activities	730.62	3089.83
B.	<u>Cash flow from investing activities</u>		
	Capital expenditure on fixed assets	128.35	225.49
	Other Income	-111.50	-142.90
	Investments	134.20	
	Net cash flow from / (used in) investing activities (B)	151.05	82.59
C.	<u>Cash flow from financing activities</u>		
	Net increase / (decrease) in working capital borrowings	46.44	-231.43
	Proceeds from other short-term borrowings	23.99	-220.08
	Repayment of other short-term borrowings		
	Finance cost	-26.58	-74.55
	Change in Foreign Currency Translation Reserve		
	Impact of Deferred Tax Assets on Foreign Currency Translation		
	Dividend paid	0.00	-65.50
	Dividends Tax paid	0.00	-13.46
	Net cash generated from / (used in) financing activities C	43.85	-605.02
	Net increase / (decrease) in Cash and cash equivalents (A+B+C)	623.42	2402.22
	Opening Balance of Cash and Cash equivalents	3853.46	1451.24
	Closing Balance of Cash and Cash equivalents	4476.88	3853.46
	Net increase / (decrease) in Cash and cash equivalents	623.42	2402.22



Notes

1. The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on November 14, 2019.
2. In line with the provisions of Ind AS 18 , the Company operates in one reportable business segment i.e. 'Pharmaceuticals'.
3. Figures for the previous periods have been regrouped , wherever necessary, to correspond with the figures of the current period
4. The above results are available on website of the company www.jagsonpal.com and on the Website of BSE (www.bseindia.com) and NSE (www.nseindia.com).
5. The Company has adopted Ind AS from April 1, 2017 and accordingly, these financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act 2013, read with relevant rules issued thereunder.
6. The revenue for the quarter ended 30-9-2019, is reported net of GST.
7. Provision for taxation includes provision for current tax.



Place : New Delhi
Date : 14-11-2019



By Order of the Board
For Jagsonpal Pharmaceuticals Limited


Rajpal Singh Kochhar
Managing Director
DIN No 00059492